|
16 Oct 2020 |
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
|
|
16 Oct 2020 |
Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
|
|
16 Oct 2020 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
16 Oct 2020 |
Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma
|
|
16 Oct 2020 |
European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
|
|
16 Oct 2020 |
Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting
|
|
16 Oct 2020 |
Alnylam Receives Positive CHMP Opinion for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups
|
|
16 Oct 2020 |
OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy
|
|
16 Oct 2020 |
Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
|
|
14 Oct 2020 |
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
|
|
13 Oct 2020 |
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
|
|
13 Oct 2020 |
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
|
|
13 Oct 2020 |
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
|
|
08 Oct 2020 |
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
|
|
08 Oct 2020 |
TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy Company
|
|
08 Oct 2020 |
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
|
|
08 Oct 2020 |
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
|
|
08 Oct 2020 |
Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers
|
|
08 Oct 2020 |
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
|
|
07 Oct 2020 |
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
|
|
07 Oct 2020 |
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
|
|
06 Oct 2020 |
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
|
|
06 Oct 2020 |
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
|
|
06 Oct 2020 |
Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
|
|
06 Oct 2020 |
Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
|
